Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

3/26/2019 7:16:18 AM Biotech Stocks Facing FDA Decision In April

3/25/2019 10:57:34 AM S&P 500 Q4 Share Repurchases Increases 62.8% T-o-y To $223.0 Bln

3/20/2019 7:46:19 AM Merck To Invest EUR 1 Bln Until 2025 At Darmstadt Site - Quick Facts

3/20/2019 7:10:19 AM Merck, NGM Bio Extend Broad, Strategic Collaboration To March 2022

3/20/2019 6:33:14 AM Merck, NGM Bio Extend Broad, Multi-Year Strategic Collaboration To 2022

3/18/2019 8:13:04 AM Merck Announces Label Expansion For KEYTRUDA In Canada - Quick Facts

3/18/2019 8:03:47 AM Merck: Health Canada Expands Label For KEYTRUDA For NSCLC, With Pemetrexed And Platinum Chemotherapy

3/14/2019 7:09:23 AM Merck: EU Approves KEYTRUDA Plus Chemotherapy To Treat Metastatic Squamous NSCLC

3/14/2019 6:48:16 AM EU Approves Merck’s KEYTRUDA In Combination With Chemotherapy For First-Line Treatment Of Adults With NSCLC

3/5/2019 7:01:20 AM Merck Begins Cash Tender Offer To Purchase Immune Design

3/4/2019 6:55:03 AM Merck : EMA Adopts Positive Opinion For KEYTRUDA

3/4/2019 6:48:33 AM Merck Says EMA Adopts Positive Opinion For KEYTRUDA Anti-PD-1 Therapy

3/1/2019 9:42:31 AM AstraZeneca : Lynparza Receives Positive EU CHMP Opinion

3/1/2019 2:52:49 AM Alzheimer's Trials That Flopped In 2018

2/26/2019 3:07:57 AM AstraZeneca, MSD Say Phase III POLO Trial Meets Primary Endpoint Of PFS

2/21/2019 11:57:41 PM IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial

2/21/2019 6:53:03 AM Merck To Buy Immune Design In $300 Mln Deal

2/21/2019 6:47:54 AM Merck To Acquire Immune Design For $5.85/Shr Cash

2/20/2019 6:58:24 AM Merck: FDA Grants Priority Review To SBLA For Keytruda Monotherapy

2/20/2019 6:48:05 AM FDA Grants Priority Review To Merck's SBLA For KEYTRUDA Monotherapy